期刊文献+

两组单克隆抗体联合检测肺癌血清中癌相关抗原的研究 被引量:1

Detection of Tumour Associated Antigen in the Sera of Lung Cancer Patients Using Two Groups of Monoclonal Antibodies
下载PDF
导出
摘要 来文报道应用我室制备的单克隆抗体(单抗)WLA2C4、CL-3、Ps-9及Ps-10,用酶联免疫ELISA结合抑制法分别测定了肺癌组及正常人组血清中癌相关抗原(TAA)的含量,并以组合方式将4株单抗分为2组测定肺癌患者血清TAA含量,其中一组还对呼吸系统良性病变患者56例进行了测定。结果表明,单株应用单抗与组合应用单抗检测正常人组及呼吸系统良性病变组血清TAA的检出率均不高,两者之间无显著差异。而单株使用单抗检测肺癌组TAA检出率分别为52%~55%,组合应用后其TAA检出率显著增高,WLA2C4与CL-3组的TAA检出率为79.3%,CL-3、Ps-9与Ps-10组的检出率为85.2%,显示了组合应用单抗良好的互补性。鉴于组合应用单抗的假阳性检出率与假阴性检出率之和小于30%,故有诊断价值。 In the present study, tumour-associated antigen (TAA) in the sera of lung cancer patients and normal subjects was determined by binding inhibition ELISA using monoclonal antibodies (McAbs) WLA2c4, CL-3, Ps-9 and PS-10 and 'cocktail' of two groups of the McAbs. In addition, sera from 56 patients with benign respiratory diseases were examined by 'cocktail' of one group of the McAbs. The results showed that TAA in normal controls and patients with benign respiratory diseases was very low whether with one McAb or 'cocktail' of McAbs. The positive rates in lung cancer patients for WLA2c4, CL-3, Ps-9, and Ps-10 ranged from 52% to 55%. When detected by 'cocktail' , the TAA positive rates were raised significantly: WLA2c4 with CL-3 and CL-3, and with Ps-9 and Ps-10 were 79.3% and 85.2%, respectively, suggesting a good complementary effect of the 'cocktail' . The sum of false positive rate and false netgative rate was less than 30%. Therefore, 'cocktailing' of McAbs is a method of great significance in diagnosis of lung cancer.
出处 《单克隆抗体通讯》 CSCD 1992年第3期18-21,共4页
关键词 诊断 TAA 肺肿瘤 单克隆抗体 lung cancer serum antibody, monoclonal turnout-associated antigen diagnosis
  • 引文网络
  • 相关文献

参考文献2

  • 1袁玫,费丽华,张小平,刘琰,张向阳,李力,李华.用单克隆抗体检测患者粪便中癌相关抗原诊断大肠癌的价值[J]细胞与分子免疫学杂志,1990(03). 被引量:1
  • 2Meenhard Herlyn,Henry F. Sears,Zenon Steplewski,Hilary Koprowski. Monoclonal antibody detection of a circulating tumor-associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma[J] 1982,Journal of Clinical Immunology(2):135~140 被引量:1

同被引文献2

引证文献1

二级引证文献2

;
使用帮助 返回顶部